
Opinion|Videos|June 16, 2025
Remaining unmet needs in diverse populations with mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing minority enrollment in clinical trials and utilizing real-world data improves drug safety and efficacy for mHSPC treatments.
Advertisement
Episodes in this series

Future Research Directions
Key Themes:
- There is a need for continued efforts to improve minority enrollment in clinical trials.
- The importance of real-world evidence to complement trial data is growing.
- A combined approach should use trial and real-world data for comprehensive assessment.
- Future research should prioritize diversity and representation.
Key Points for Physicians:
- Stay informed about evolving evidence from clinical trials and real-world data.
- Support efforts to improve diversity in research.
- Consider contributing to real-world evidence generation.
- Recognize limitations in current evidence while awaiting more comprehensive data.
Notable Insights: Real-world evidence provides an important complement to clinical trial data, particularly for understanding outcomes in traditionally underrepresented populations.
Clinical Significance: Ongoing commitment to inclusive research and evidence generation will improve the quality and equity of prostate cancer care, particularly for populations historically underrepresented in clinical trials.
Advertisement
Related to this article

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5

